Paper · 35176457

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.

Subbiah V and 9 others. Ann Oncol, 2022. Cited by 172 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Papers, record 35176457. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35176457

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.; PubMed
Journal: Ann Oncol; PubMed
Year: 2022; PubMed
Publication types: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/35176457/; PubMed
DOI: https://doi.org/10.1016/j.annonc.2022.02.001; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11961695/; PubMed
The journal: https://conductscience.org/library/journal-index/9007735; PubMed
Citations, by iCite: 172; iCite
Relative citation ratio, by iCite: 11; iCite
Revised in PubMed: 2025-04-04; PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Subbiah V	V
2	Iannotti NO	N O
3	Gutierrez M	M
4	Smith DC	D C
5	Féliz L	L
6	Lihou CF	C F
7	Tian C	C
8	Silverman IM	I M
9	Ji T	T
10	Saleh M	M

Source PubMed

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Bile Duct Neoplasms	Major topic
Carcinoma, Non-Small-Cell Lung	Major topic
Carcinoma, Transitional Cell	Major topic
Cholangiocarcinoma	Major topic
Lung Neoplasms	Major topic
Neoplasms	Major topic
Urinary Bladder Neoplasms	Major topic
Bile Ducts, Intrahepatic
Female
Fibroblast Growth Factors
Humans
Male
Morpholines
Neoplasm Recurrence, Local
Protein Kinase Inhibitors
Pyrimidines
Pyrroles
Receptors, Fibroblast Growth Factor

Source PubMed

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
P30 CA016672	NCI NIH HHS	United States	P30CA016672	PubMed and NIH	NIH RePORTER
R01 CA242845	NCI NIH HHS	United States	R01CA242845	PubMed and NIH	NIH RePORTER
U01 CA180964	NCI NIH HHS	United States	U01CA180964	PubMed and NIH	NIH RePORTER
UL1 TR000371	NCATS NIH HHS	United States	UL1TR000371	PubMed and NIH	NIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT02393248	Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)	Derived from the trial	Yes

Source ClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Comment in	35,450,697	FIGHT against FGF/FGFR alterations: what are the next steps?	https://conductscience.org/library/papers/35450697

Source PubMed

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	29,848,605	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.	Cancer Discov	2018	https://conductscience.org/library/papers/29848605	PubMed
2	22,388,515	Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.	Clin Cancer Res	2012	https://conductscience.org/library/papers/22388515	PubMed
3	33,268,819	Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.	Br J Cancer	2021	https://conductscience.org/library/papers/33268819	PubMed
4	31,088,831	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.	Clin Cancer Res	2019	https://conductscience.org/library/papers/31088831	PubMed
5	31,340,094	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.	N Engl J Med	2019	https://conductscience.org/library/papers/31340094	PubMed
6	26,078,430	Targeting FGFR Signaling in Cancer.	Clin Cancer Res	2015	https://conductscience.org/library/papers/26078430	PubMed
7	33,887,300	Molecular pathology of urothelial carcinoma.	Hum Pathol	2021	https://conductscience.org/library/papers/33887300	PubMed
8	34,199,304	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice.	Cancers (Basel)	2021	https://conductscience.org/library/papers/34199304	PubMed
9	26,373,574	The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.	Clin Cancer Res	2016	https://conductscience.org/library/papers/26373574	PubMed
10	31,585,937	Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors.	Clin Cancer Res	2020	https://conductscience.org/library/papers/31585937	PubMed

1 to 10 of 24

See all 24 references

Cited by119

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 172 citations.

PMID	Title	Journal	Year	In Papers	Source
42,827,286	A Real-World Study of Patients with FGFR-Altered Advanced Solid Tumors after Exhaustion of Standard-of-Care Treatment.	Cancer Res Commun	2026	https://conductscience.org/library/papers/42827286	PubMed
42,542,997	FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials.	Target Oncol	2026	https://conductscience.org/library/papers/42542997	PubMed
42,406,058	The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.	Cancer Chemother Pharmacol	2026	https://conductscience.org/library/papers/42406058	PubMed
42,177,363	FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.	Commun Biol	2026	https://conductscience.org/library/papers/42177363	PubMed
42,146,765	Research on Targeted Therapy for Malignant Tumors of the Biliary Tract.	Onco Targets Ther	2026	https://conductscience.org/library/papers/42146765	PubMed
42,087,217	Comprehensive molecular characterization identifies therapeutic vulnerabilities in ovarian clear cell carcinoma.	Genome Med	2026	https://conductscience.org/library/papers/42087217	PubMed
41,799,559	Holistic Treatment Incorporating Moist Wound Healing for Postoperative Radiation-Induced Perineal Ulcer in Rectal Malignancy: A Case Report.	Case Rep Dermatol	2026	https://conductscience.org/library/papers/41799559	PubMed
41,773,262	Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps.	Drug Des Devel Ther	2026	https://conductscience.org/library/papers/41773262	PubMed
41,764,695	Ligand-based graph neural network, molecular dynamics and biological evaluation for identification of potential FGFR1 kinase inhibitors.	Mol Divers	2026	https://conductscience.org/library/papers/41764695	PubMed
41,646,477	A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer.	ESMO Gastrointest Oncol	2025	https://conductscience.org/library/papers/41646477	PubMed

1 to 10 of 119

See all 119 cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
FGFR1	2,260	PubTator's text mining	https://conductscience.org/library/genes/2260	NCBI Gene
FGFR2	2,263	PubTator's text mining	https://conductscience.org/library/genes/2263	NCBI Gene
FGFR3	2,261	PubTator's text mining	https://conductscience.org/library/genes/2261	NCBI Gene

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets
PEMIGATINIB	CHEMBL4297522	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL4297522

Source ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35176457

GET https://conductscience.org/api/papers/v1/35176457/references?page=2

API reference For AI assistants